The streak of positive Keytruda updates had to end somewhere. After an onslaught of upbeat trial results and regulatory news, maker Merck Monday night announced that it was pausing enrollment on a pair of phase 3 multiple myeloma studies of the med to investigate trial deaths.
In unexpected blow, Merck halts Keytruda myeloma trial enrollment to probe patient deaths
Leave a Comment